Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
FPI-1434 by Fusion Pharmaceuticals for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
FPI-1434 by Fusion Pharmaceuticals for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
FPI-1434 by Fusion Pharmaceuticals for Uveal Melanoma: Likelihood of Approval
FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase...
FPI-1434 by Fusion Pharmaceuticals for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
FPI-1434 by Fusion Pharmaceuticals for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval
FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According...
FPI-1434 by Fusion Pharmaceuticals for Endometrial Cancer: Likelihood of Approval
FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
FPI-1434 by Fusion Pharmaceuticals for Cervical Cancer: Likelihood of Approval
FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
FPI-1434 by Fusion Pharmaceuticals for Ovarian Cancer: Likelihood of Approval
FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
FPI-1434 by Fusion Pharmaceuticals for Ewing Sarcoma: Likelihood of Approval
FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Ewing Sarcoma. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Fusion Pharmaceuticals's FPI-1434?
FPI-1434 is a monoclonal antibody conjugated commercialized by Fusion Pharmaceuticals, with a leading Phase II program in Cervical Cancer. According...
Risk adjusted net present value: What is the current valuation of Fusion Pharmaceuticals's FPI-1434?
FPI-1434 is a monoclonal antibody conjugated commercialized by Fusion Pharmaceuticals, with a leading Phase II program in Cervical Cancer. According...